###begin article-title 0
Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer
###end article-title 0
###begin p 1
###xml 1492 1493 1492 1493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1549 1550 1549 1550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 464 468 <span type="species:ncbi:10090">mice</span>
###xml 583 591 <span type="species:ncbi:9606">patients</span>
Fanconi anemia (FA) is a recessive disorder associated with progressive pancytopenia, multiple developmental defects, and marked predisposition to malignancies. FA is genetically heterogeneous, comprising at least 12 complementation groups (A-M). Activation of one of the FA proteins (FANCD2) by mono-ubiquitination is an essential step in DNA damage response. As FANCD2 interacts with BRCA1, is expressed in proliferating normal breast cells, and FANCD2 knockout mice develop breast tumors, we investigated the expression of FANCD2 in sporadic and hereditary invasive breast cancer patients to evaluate its possible role in breast carcinogenesis. Two tissue microarrays of 129 and 220 sporadic breast cancers and a tissue microarray containing 25 BRCA1 germline mutation-related invasive breast cancers were stained for FANCD2. Expression results were compared with several clinicopathological variables and tested for prognostic value. Eighteen of 96 (19%) sporadic breast cancers and two of 21 (10%) BRCA1-related breast cancers were completely FANCD2-negative, which, however, still showed proliferation. In the remaining cases, the percentage of FANCD2-expressing cells correlated strongly with mitotic index and percentage of cells positive for the proliferation markers Ki-67 and Cyclin A. In immunofluorescence double staining, coexpression of FANCD2 and Ki-67 was apparent. In survival analysis, high FANCD2 expression appeared to be prognostically unfavorable for overall survival (p = 0.03), independent from other major prognosticators (p = 0.026). In conclusion, FANCD2 expression is absent in 10-20% of sporadic and BRCA1-related breast cancers, indicating that somatic inactivating (epi)genetic events in FANCD2 may be important in both sporadic and hereditary breast carcinogenesis. FANCD2 is of independent prognostic value in sporadic breast cancer.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 576 581 576 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FANCA</italic>
###xml 583 588 583 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FANCB</italic>
###xml 590 595 590 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FANCC</italic>
###xml 597 603 597 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FANCD1</italic>
###xml 604 609 604 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 611 617 611 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FANCD2</italic>
###xml 619 624 619 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FANCE</italic>
###xml 626 631 626 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FANCF</italic>
###xml 633 638 633 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FANCG</italic>
###xml 640 645 640 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FANCJ</italic>
###xml 647 652 647 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FANCL</italic>
###xml 658 663 658 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FANCM</italic>
###xml 665 666 665 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 962 963 962 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 965 967 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1056 1061 1056 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 1066 1071 1066 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 1250 1252 1250 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1254 1256 1254 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1516 1518 1516 1518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 1584 1586 1584 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 1644 1646 1644 1646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 1831 1833 1831 1833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 1975 1977 1975 1977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 2207 2209 2207 2209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 2179 2183 <span type="species:ncbi:10090">mice</span>
Fanconi anemia (FA) is a recessive disease with both autosomal and X-linked inheritance. FA is associated with progressive pancytopenia, developmental defects, and marked predisposition to malignancies, especially acute myeloid leukemia and squamous cell carcinoma of the head and neck [1, 2]. FA cells are characterized by spontaneous chromosomal instability and hypersensitivity to DNA cross-linking agents such as mitomycin C (MMC). FA is genetically heterogeneous and comprises at least 12 complementation groups (A-M). Eleven of the FA genes have been identified so far: FANCA, FANCB, FANCC, FANCD1/BRCA2, FANCD2, FANCE, FANCF, FANCG, FANCJ, FANCL, and FANCM [3-18]. Eight FA proteins (A, B, C, E, F, G, L, and M) form a nuclear protein complex which is required for mono-ubiquitination of the downstream FA protein, FANCD2. Activation of FANCD2 by mono-ubiquitination is an essential step in the DNA damage response induced by MMC or ionizing irradiation [2, 10]. This DNA damage response pathway also includes the breast cancer susceptibility genes BRCA1 and BRCA2, also referred to as the FA-BRCA pathway. Following ionizing radiation, FANCD2 and BRCA1 accumulate and colocalize in nuclear foci, which reflect sites of DNA damage and repair [10, 19]. Like FA cells, cells lacking BRCA1/2 proteins are hypersensitive to DNA cross-linking agents. D'Andrea et al. showed that FANCD1 and BRCA2 are the same proteins. BRCA2 is a direct regulator of RAD51, a protein essential for homologous recombination repair [20]. Although BRCA1 is mainly involved in hereditary breast cancer [21], it has also been implicated in sporadic breast cancer [22]. In an immunohistochemical analysis, we have previously shown that FANCD2 is expressed in proliferating cells of different organs, including the premenopausal breast duct epithelium [23]. This is in line with the role of FANCD2 in DNA repair which is important to guarantee the integrity of the genome during cell replication [10]. As deregulation of proliferation is one of the crucial processes of carcinogenesis, these observations imply a potential role for FANCD2 in the pathogenesis of breast cancer. Indeed, FANCD2 knockout mice develop breast tumors [24]. These considerations prompted us to investigate the expression of FANCD2 in sporadic and hereditary invasive breast cancers by immunohistochemistry in relation to several other proliferation-related biomarkers and survival.
###end p 4
###begin title 5
Materials and methods
###end title 5
###begin title 6
Tissue microarray
###end title 6
###begin p 7
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 612 613 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 1193 1195 1193 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1198 1205 1198 1205 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1205 1288 1205 1288 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="8">Patient characteristics and histology of 120 sporadic and hereditary breast cancers</p>
###xml 1205 1288 1205 1288 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="8">Patient characteristics and histology of 120 sporadic and hereditary breast cancers</p></caption>
###xml 1288 1288 1288 1288 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1288 1296 1288 1296 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Sporadic</th>
###xml 1296 1310 1296 1310 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BRCA1 mutation</th>
###xml 1310 1315 1310 1315 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Total</th>
###xml 1288 1315 1288 1315 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left">Sporadic</th><th align="left">BRCA1 mutation</th><th align="left">Total</th></tr>
###xml 1288 1315 1288 1315 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"/><th align="left">Sporadic</th><th align="left">BRCA1 mutation</th><th align="left">Total</th></tr></thead>
###xml 1315 1330 1315 1330 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No. of patients</td>
###xml 1330 1332 1330 1332 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">96</td>
###xml 1332 1334 1332 1334 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">24</td>
###xml 1334 1337 1334 1337 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">120</td>
###xml 1315 1337 1315 1337 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">No. of patients</td><td align="left">96</td><td align="left">24</td><td align="left">120</td></tr>
###xml 1337 1340 1337 1340 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" colspan="4">Age</td>
###xml 1337 1340 1337 1340 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char" colspan="4">Age</td></tr>
###xml 1340 1347 1340 1347 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Mean</td>
###xml 1347 1349 1347 1349 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">65</td>
###xml 1349 1351 1349 1351 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">42</td>
###xml 1351 1353 1351 1353 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">62</td>
###xml 1340 1353 1340 1353 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Mean</td><td char="." align="char">65</td><td char="." align="char">42</td><td char="." align="char">62</td></tr>
###xml 1353 1370 1353 1370 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" colspan="4">Lymph node status</td>
###xml 1353 1370 1353 1370 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char" colspan="4">Lymph node status</td></tr>
###xml 1370 1381 1370 1381 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Negative</td>
###xml 1381 1383 1381 1383 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">58</td>
###xml 1383 1384 1383 1384 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9</td>
###xml 1384 1386 1384 1386 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">67</td>
###xml 1370 1386 1370 1386 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Negative</td><td char="." align="char">58</td><td char="." align="char">9</td><td char="." align="char">67</td></tr>
###xml 1386 1397 1386 1397 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Positive</td>
###xml 1397 1399 1397 1399 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38</td>
###xml 1399 1401 1399 1401 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 1401 1403 1401 1403 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">49</td>
###xml 1386 1403 1386 1403 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Positive</td><td char="." align="char">38</td><td char="." align="char">11</td><td char="." align="char">49</td></tr>
###xml 1403 1413 1403 1413 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" colspan="4">Tumor size</td>
###xml 1403 1413 1403 1413 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char" colspan="4">Tumor size</td></tr>
###xml 1413 1420 1413 1420 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Mean</td>
###xml 1420 1424 1420 1424 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.34</td>
###xml 1424 1428 1424 1428 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.78</td>
###xml 1428 1432 1428 1432 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.40</td>
###xml 1413 1432 1413 1432 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Mean</td><td char="." align="char">2.34</td><td char="." align="char">2.78</td><td char="." align="char">2.40</td></tr>
###xml 1432 1449 1432 1449 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" colspan="4">Histological type</td>
###xml 1432 1449 1432 1449 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char" colspan="4">Histological type</td></tr>
###xml 1449 1458 1449 1458 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Ductal</td>
###xml 1458 1460 1458 1460 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">85</td>
###xml 1460 1462 1460 1462 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">17</td>
###xml 1462 1465 1462 1465 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">102</td>
###xml 1449 1465 1449 1465 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Ductal</td><td char="." align="char">85</td><td char="." align="char">17</td><td char="." align="char">102</td></tr>
###xml 1465 1475 1465 1475 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Lobular</td>
###xml 1475 1476 1475 1476 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7</td>
###xml 1476 1477 1476 1477 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1477 1478 1477 1478 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8</td>
###xml 1465 1478 1465 1478 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Lobular</td><td char="." align="char">7</td><td char="." align="char">1</td><td char="." align="char">8</td></tr>
###xml 1478 1490 1478 1490 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Medullary</td>
###xml 1490 1491 1490 1491 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1491 1492 1491 1492 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1492 1493 1492 1493 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 1478 1493 1478 1493 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Medullary</td><td char="." align="char">1</td><td char="." align="char">2</td><td char="." align="char">3</td></tr>
###xml 1493 1503 1493 1503 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Tubular</td>
###xml 1503 1504 1503 1504 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1504 1505 1504 1505 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8211;</td>
###xml 1505 1506 1505 1506 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1493 1506 1493 1506 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Tubular</td><td char="." align="char">1</td><td char="." align="char">&#8211;</td><td char="." align="char">1</td></tr>
###xml 1506 1519 1506 1519 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Cribriform</td>
###xml 1519 1520 1519 1520 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1520 1521 1520 1521 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8211;</td>
###xml 1521 1522 1521 1522 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1506 1522 1506 1522 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Cribriform</td><td char="." align="char">1</td><td char="." align="char">&#8211;</td><td char="." align="char">1</td></tr>
###xml 1522 1533 1522 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Apocrine</td>
###xml 1533 1534 1533 1534 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1534 1535 1534 1535 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8211;</td>
###xml 1535 1536 1535 1536 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1522 1536 1522 1536 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Apocrine</td><td char="." align="char">1</td><td char="." align="char">&#8211;</td><td char="." align="char">1</td></tr>
###xml 1536 1550 1536 1550 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Metaplastic</td>
###xml 1550 1551 1550 1551 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8211;</td>
###xml 1551 1552 1551 1552 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 1552 1553 1552 1553 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 1536 1553 1536 1553 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Metaplastic</td><td char="." align="char">&#8211;</td><td char="." align="char">4</td><td char="." align="char">4</td></tr>
###xml 1315 1553 1315 1553 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">No. of patients</td><td align="left">96</td><td align="left">24</td><td align="left">120</td></tr><tr><td char="." align="char" colspan="4">Age</td></tr><tr><td align="left">&#160;&#160;&#160;Mean</td><td char="." align="char">65</td><td char="." align="char">42</td><td char="." align="char">62</td></tr><tr><td char="." align="char" colspan="4">Lymph node status</td></tr><tr><td align="left">&#160;&#160;&#160;Negative</td><td char="." align="char">58</td><td char="." align="char">9</td><td char="." align="char">67</td></tr><tr><td align="left">&#160;&#160;&#160;Positive</td><td char="." align="char">38</td><td char="." align="char">11</td><td char="." align="char">49</td></tr><tr><td char="." align="char" colspan="4">Tumor size</td></tr><tr><td align="left">&#160;&#160;&#160;Mean</td><td char="." align="char">2.34</td><td char="." align="char">2.78</td><td char="." align="char">2.40</td></tr><tr><td char="." align="char" colspan="4">Histological type</td></tr><tr><td align="left">&#160;&#160;&#160;Ductal</td><td char="." align="char">85</td><td char="." align="char">17</td><td char="." align="char">102</td></tr><tr><td align="left">&#160;&#160;&#160;Lobular</td><td char="." align="char">7</td><td char="." align="char">1</td><td char="." align="char">8</td></tr><tr><td align="left">&#160;&#160;&#160;Medullary</td><td char="." align="char">1</td><td char="." align="char">2</td><td char="." align="char">3</td></tr><tr><td align="left">&#160;&#160;&#160;Tubular</td><td char="." align="char">1</td><td char="." align="char">&#8211;</td><td char="." align="char">1</td></tr><tr><td align="left">&#160;&#160;&#160;Cribriform</td><td char="." align="char">1</td><td char="." align="char">&#8211;</td><td char="." align="char">1</td></tr><tr><td align="left">&#160;&#160;&#160;Apocrine</td><td char="." align="char">1</td><td char="." align="char">&#8211;</td><td char="." align="char">1</td></tr><tr><td align="left">&#160;&#160;&#160;Metaplastic</td><td char="." align="char">&#8211;</td><td char="." align="char">4</td><td char="." align="char">4</td></tr></tbody>
###xml 1288 1553 1288 1553 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Sporadic</th><th align="left">BRCA1 mutation</th><th align="left">Total</th></tr></thead><tbody><tr><td align="left">No. of patients</td><td align="left">96</td><td align="left">24</td><td align="left">120</td></tr><tr><td char="." align="char" colspan="4">Age</td></tr><tr><td align="left">&#160;&#160;&#160;Mean</td><td char="." align="char">65</td><td char="." align="char">42</td><td char="." align="char">62</td></tr><tr><td char="." align="char" colspan="4">Lymph node status</td></tr><tr><td align="left">&#160;&#160;&#160;Negative</td><td char="." align="char">58</td><td char="." align="char">9</td><td char="." align="char">67</td></tr><tr><td align="left">&#160;&#160;&#160;Positive</td><td char="." align="char">38</td><td char="." align="char">11</td><td char="." align="char">49</td></tr><tr><td char="." align="char" colspan="4">Tumor size</td></tr><tr><td align="left">&#160;&#160;&#160;Mean</td><td char="." align="char">2.34</td><td char="." align="char">2.78</td><td char="." align="char">2.40</td></tr><tr><td char="." align="char" colspan="4">Histological type</td></tr><tr><td align="left">&#160;&#160;&#160;Ductal</td><td char="." align="char">85</td><td char="." align="char">17</td><td char="." align="char">102</td></tr><tr><td align="left">&#160;&#160;&#160;Lobular</td><td char="." align="char">7</td><td char="." align="char">1</td><td char="." align="char">8</td></tr><tr><td align="left">&#160;&#160;&#160;Medullary</td><td char="." align="char">1</td><td char="." align="char">2</td><td char="." align="char">3</td></tr><tr><td align="left">&#160;&#160;&#160;Tubular</td><td char="." align="char">1</td><td char="." align="char">&#8211;</td><td char="." align="char">1</td></tr><tr><td align="left">&#160;&#160;&#160;Cribriform</td><td char="." align="char">1</td><td char="." align="char">&#8211;</td><td char="." align="char">1</td></tr><tr><td align="left">&#160;&#160;&#160;Apocrine</td><td char="." align="char">1</td><td char="." align="char">&#8211;</td><td char="." align="char">1</td></tr><tr><td align="left">&#160;&#160;&#160;Metaplastic</td><td char="." align="char">&#8211;</td><td char="." align="char">4</td><td char="." align="char">4</td></tr></tbody></table>
###xml 1198 1553 1198 1553 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="8">Patient characteristics and histology of 120 sporadic and hereditary breast cancers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Sporadic</th><th align="left">BRCA1 mutation</th><th align="left">Total</th></tr></thead><tbody><tr><td align="left">No. of patients</td><td align="left">96</td><td align="left">24</td><td align="left">120</td></tr><tr><td char="." align="char" colspan="4">Age</td></tr><tr><td align="left">&#160;&#160;&#160;Mean</td><td char="." align="char">65</td><td char="." align="char">42</td><td char="." align="char">62</td></tr><tr><td char="." align="char" colspan="4">Lymph node status</td></tr><tr><td align="left">&#160;&#160;&#160;Negative</td><td char="." align="char">58</td><td char="." align="char">9</td><td char="." align="char">67</td></tr><tr><td align="left">&#160;&#160;&#160;Positive</td><td char="." align="char">38</td><td char="." align="char">11</td><td char="." align="char">49</td></tr><tr><td char="." align="char" colspan="4">Tumor size</td></tr><tr><td align="left">&#160;&#160;&#160;Mean</td><td char="." align="char">2.34</td><td char="." align="char">2.78</td><td char="." align="char">2.40</td></tr><tr><td char="." align="char" colspan="4">Histological type</td></tr><tr><td align="left">&#160;&#160;&#160;Ductal</td><td char="." align="char">85</td><td char="." align="char">17</td><td char="." align="char">102</td></tr><tr><td align="left">&#160;&#160;&#160;Lobular</td><td char="." align="char">7</td><td char="." align="char">1</td><td char="." align="char">8</td></tr><tr><td align="left">&#160;&#160;&#160;Medullary</td><td char="." align="char">1</td><td char="." align="char">2</td><td char="." align="char">3</td></tr><tr><td align="left">&#160;&#160;&#160;Tubular</td><td char="." align="char">1</td><td char="." align="char">&#8211;</td><td char="." align="char">1</td></tr><tr><td align="left">&#160;&#160;&#160;Cribriform</td><td char="." align="char">1</td><td char="." align="char">&#8211;</td><td char="." align="char">1</td></tr><tr><td align="left">&#160;&#160;&#160;Apocrine</td><td char="." align="char">1</td><td char="." align="char">&#8211;</td><td char="." align="char">1</td></tr><tr><td align="left">&#160;&#160;&#160;Metaplastic</td><td char="." align="char">&#8211;</td><td char="." align="char">4</td><td char="." align="char">4</td></tr></tbody></table></table-wrap>
###xml 569 576 <span type="species:ncbi:9606">Patient</span>
###xml 1033 1041 <span type="species:ncbi:9606">patients</span>
Paraffin blocks containing formaldehyde-fixed breast cancer tissues of 129 cases of invasive breast cancer not selected for family history (further denoted "sporadic") were obtained from the archives of the Department of Pathology of the VU University Medical Center, Amsterdam. For all breast cancer cases, age, lymph node status, and tumor size were documented. A second array block was constructed containing 24 cases with a proven BRCA1 germline mutation identified through the Family Cancer Clinic of the VU University Medical Center as previously described [25]. Patient characteristics are shown in Table 1. The hematoxylin-eosin stainings were used to identify representative areas of tumor tissue in the blocks. A tissue microarray was then constructed by transferring tissue cylinders of 4-5 mm from the representative tumor area of each donor block to the recipient block using a tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA) as described before [26]. A third tissue array block of 220 sporadic breast cancer patients with long-term follow-up was obtained from the archives of the Gerhard-Domagk Institute of Pathology, University of Muenster, as previously described [27]. Table 1Patient characteristics and histology of 120 sporadic and hereditary breast cancersSporadicBRCA1 mutationTotalNo. of patients9624120Age   Mean654262Lymph node status   Negative58967   Positive381149Tumor size   Mean2.342.782.40Histological type   Ductal8517102   Lobular718   Medullary123   Tubular1-1   Cribriform1-1   Apocrine1-1   Metaplastic-44
###end p 7
###begin p 8
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics and histology of 120 sporadic and hereditary breast cancers
###end p 8
###begin p 9
###xml 260 262 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
Sections of 4 mum were cut and transferred on SuperFrost+ (Menzel&Glaeser, Germany) slides for immunohistochemistry. Use of anonymous or coded left over material for scientific purposes is part of the standard treatment contract with patients in our hospital [28].
###end p 9
###begin title 10
Immunohistochemistry
###end title 10
###begin p 11
###xml 201 204 201 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
Immunohistochemical analysis had been previously performed on conventional sections for the following markers: Ki-67, Cyclin A, p21, p27, p53, estrogen receptor (ER), progesterone receptor (PR), HER-2/neu, and EGF-receptor [29].
###end p 11
###begin p 12
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 193 194 193 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 195 196 195 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 0 6 <span type="species:ncbi:9986">Rabbit</span>
###xml 330 334 <span type="species:ncbi:9925">goat</span>
###xml 374 380 <span type="species:ncbi:9986">rabbit</span>
Rabbit polyclonal antiserum against FANCD2 was generated as previously described [23]. Tissue sections were deparaffinized and rehydrated. Endogenous peroxidase was blocked with methanol/0.3% H2O2 (20 min). Sections were heated (30 min, 120degreesC) in 0.1 M citrate buffer pH 6. Unspecific binding was blocked with a 1:50 normal goat serum in PBS pH 7.4/1% BSA. Polyclonal rabbit anti-FANCD2 (200 mug/ml) was diluted 1:500 in PBS/1% BSA, and sections were incubated overnight (4degreesC) in a humidified chamber. Subsequently, sections were incubated with HRP-conjugated secondary antibodies (EnVision, DAKO) and diaminobenzidin (10 min), counterstained with hematoxylin (20 s), dehydrated, and cover-slipped. Appropriate positive controls were used throughout, and negative controls were obtained by omission of the primary antibodies.
###end p 12
###begin p 13
###xml 112 115 112 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
Percentages of positively stained nuclei were estimated by an experienced observer (P.J.v.D.), except for HER-2/neu and EGF-receptor where membrane staining was scored as positive. In addition, FANCD2 intensity was scored semiquantitatively as 0-3, and an FANCD2 score was calculated for each case by multiplying the % FANCD2-positive cells by the staining intensity.
###end p 13
###begin p 14
###xml 575 577 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 114 119 <span type="species:ncbi:9823">swine</span>
###xml 125 131 <span type="species:ncbi:9986">Rabbit</span>
###xml 324 329 <span type="species:ncbi:10090">mouse</span>
###xml 396 402 <span type="species:ncbi:9986">rabbit</span>
###xml 408 413 <span type="species:ncbi:10090">mouse</span>
For FANCD2/Ki-67 double staining, anti-FANCD2 was diluted 1:150, incubated overnight, followed by incubation with swine anti-Rabbit HRP 1:200 (Dako, Glostrup, Denmark), and detected with the TSAtrade mark Tetramethylrhodamine system (PerkinElmer Life Sciences, Boston, USA). This was immediately followed by incubation with mouse anti-Ki-67 1:50 (MIB1, Immunotech, Marseille, France) followed by rabbit anti-mouse FITC 1:40 (Dako, Glostrup, Denmark). Nuclei were counterstained by incubation with TO-PRO-3 (Molecular Probes, Eugene, OR, USA) 1:5,000 as previously described [30].
###end p 14
###begin title 15
Statistics
###end title 15
###begin p 16
###xml 401 402 401 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 415 416 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 451 452 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 557 560 557 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 187 190 <span type="species:ncbi:55883?0.49606299212598426">MAI</span>
Bivariate scatter plots were generated between the percentage of FANCD2-expressing cells and the other continuous features. For the proliferation-associated features Ki-67, Cyclin A, and MAI, the cases with no FANCD2 expression were excluded from the analysis, assuming that FANCD2 is, by some mechanisms, no longer expressed in these cases. By linear regression analysis, the correlation coefficient R and related p values were calculated. Student's t test was used to compare FANCD2 expression levels between the low-level vs. high-level groups for HER-2/neu, the EGF-receptor, ER (cut off 10%) and PR (cut off 10%), p53 (cut off 10%), and Cyclin D1 (cut off 5%). Prognostic value of FANCD2 (Muenster cases) was assessed by computing Kaplan-Meier curves, and differences between the curves were evaluated with the log-rank test. Multivariate survival analysis was performed by Cox regression.
###end p 16
###begin title 17
Results
###end title 17
###begin p 18
###xml 498 499 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 555 561 555 561 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 561 689 561 689 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="19">Examples of FANCD2 staining in sporadic (A/B, A&#160;=&#160;negative control) and BRCA1-related breast cancers (C/D, C&#160;=&#160;negative control)</p>
###xml 561 689 561 689 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="19">Examples of FANCD2 staining in sporadic (A/B, A&#160;=&#160;negative control) and BRCA1-related breast cancers (C/D, C&#160;=&#160;negative control)</p></caption>
###xml 689 689 689 689 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10549_2007_9534_Fig1_HTML" id="MO1"/>
###xml 555 689 555 689 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="19">Examples of FANCD2 staining in sporadic (A/B, A&#160;=&#160;negative control) and BRCA1-related breast cancers (C/D, C&#160;=&#160;negative control)</p></caption><graphic position="anchor" xlink:href="10549_2007_9534_Fig1_HTML" id="MO1"/></fig>
Successful FANCD2 staining was performed in 96 of the 129 cases of the VUmc sporadic array block. The drop outs were caused by damaged or detached cores during cutting, mounting, or staining, or did not contain tumor. Eighteen of these cases (19%) were completely FANCD2-negative. The other cases showed variable staining from 1 to 85% of the nuclei. In 21 of the 24 BRCA1 cases, FANCD2 staining was performed successfully. In two of these (9.5%), FANCD2 expression was completely negative. Figure 1 shows some representative examples of FANCD2 staining. Fig. 1Examples of FANCD2 staining in sporadic (A/B, A = negative control) and BRCA1-related breast cancers (C/D, C = negative control)
###end p 18
###begin p 19
Examples of FANCD2 staining in sporadic (A/B, A = negative control) and BRCA1-related breast cancers (C/D, C = negative control)
###end p 19
###begin p 20
###xml 97 98 97 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 131 132 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 167 168 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 247 248 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 328 332 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu.</italic>
###xml 634 641 634 641 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 641 830 641 830 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="21">Mean percentage of FANCD2-positive cells in high- and low-level expression groups of hormone receptors, growth factor receptors, Cyclin D1, and p53 in sporadic and hereditary breast cancers</p>
###xml 641 830 641 830 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="21">Mean percentage of FANCD2-positive cells in high- and low-level expression groups of hormone receptors, growth factor receptors, Cyclin D1, and p53 in sporadic and hereditary breast cancers</p></caption>
###xml 830 830 830 830 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 830 840 830 840 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Number (%)</th>
###xml 840 860 840 860 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean (SE) of FANCD2%</th>
###xml 860 861 860 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 869 870 869 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 860 876 860 876 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>p</italic> Value (<italic>t</italic> test)</th>
###xml 830 876 830 876 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left">Number (%)</th><th align="left">Mean (SE) of FANCD2%</th><th align="left"><italic>p</italic> Value (<italic>t</italic> test)</th></tr>
###xml 830 876 830 876 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"/><th align="left">Number (%)</th><th align="left">Mean (SE) of FANCD2%</th><th align="left"><italic>p</italic> Value (<italic>t</italic> test)</th></tr></thead>
###xml 876 881 876 881 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Total</td>
###xml 881 890 881 890 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">117 (100)</td>
###xml 890 890 890 890 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 890 890 890 890 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 876 890 876 890 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Total</td><td char="(" align="char">117 (100)</td><td align="left"/><td align="left"/></tr>
###xml 890 892 890 892 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">ER</td>
###xml 890 892 890 892 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">ER</td></tr>
###xml 892 898 892 898 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Low</td>
###xml 898 905 898 905 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">56 (48)</td>
###xml 905 913 905 913 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">14 (2.5)</td>
###xml 913 918 913 918 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.019</td>
###xml 892 918 892 918 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">56 (48)</td><td char="." align="char">14 (2.5)</td><td char="." align="char">0.019</td></tr>
###xml 918 925 918 925 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;High</td>
###xml 925 932 925 932 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">61 (52)</td>
###xml 932 939 932 939 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8 (1.6)</td>
###xml 939 939 939 939 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 918 939 918 939 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">61 (52)</td><td char="." align="char">8 (1.6)</td><td char="." align="char"/></tr>
###xml 939 941 939 941 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">PR</td>
###xml 939 941 939 941 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">PR</td></tr>
###xml 941 947 941 947 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Low</td>
###xml 947 954 947 954 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">81 (69)</td>
###xml 954 962 954 962 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">17 (1.9)</td>
###xml 962 967 962 967 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.016</td>
###xml 941 967 941 967 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">81 (69)</td><td char="." align="char">17 (1.9)</td><td char="." align="char">0.016</td></tr>
###xml 967 974 967 974 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;High</td>
###xml 974 981 974 981 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">36 (31)</td>
###xml 981 989 981 989 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12 (1.9)</td>
###xml 989 989 989 989 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 967 989 967 989 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">36 (31)</td><td char="." align="char">12 (1.9)</td><td char="." align="char"/></tr>
###xml 995 998 995 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 989 998 989 998 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">HER-2/<italic>neu</italic></td>
###xml 989 998 989 998 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">HER-2/<italic>neu</italic></td></tr>
###xml 998 1009 998 1009 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Negative</td>
###xml 1009 1016 1009 1016 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">93 (79)</td>
###xml 1016 1024 1016 1024 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16 (1.6)</td>
###xml 1024 1029 1024 1029 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.797</td>
###xml 998 1029 998 1029 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Negative</td><td char="(" align="char">93 (79)</td><td char="." align="char">16 (1.6)</td><td char="." align="char">0.797</td></tr>
###xml 1029 1040 1029 1040 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Positive</td>
###xml 1040 1047 1040 1047 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">24 (21)</td>
###xml 1047 1055 1047 1055 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">17 (3.5)</td>
###xml 1055 1055 1055 1055 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1029 1055 1029 1055 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Positive</td><td char="(" align="char">24 (21)</td><td char="." align="char">17 (3.5)</td><td char="." align="char"/></tr>
###xml 1055 1067 1055 1067 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">EGF receptor</td>
###xml 1055 1067 1055 1067 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">EGF receptor</td></tr>
###xml 1067 1078 1067 1078 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Negative</td>
###xml 1078 1085 1078 1085 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">78 (66)</td>
###xml 1085 1093 1085 1093 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13 (1.5)</td>
###xml 1093 1098 1093 1098 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.002</td>
###xml 1067 1098 1067 1098 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Negative</td><td char="(" align="char">78 (66)</td><td char="." align="char">13 (1.5)</td><td char="." align="char">0.002</td></tr>
###xml 1098 1109 1098 1109 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Positive</td>
###xml 1109 1116 1109 1116 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">39 (33)</td>
###xml 1116 1124 1116 1124 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">19 (3.1)</td>
###xml 1124 1124 1124 1124 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1098 1124 1098 1124 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Positive</td><td char="(" align="char">39 (33)</td><td char="." align="char">19 (3.1)</td><td char="." align="char"/></tr>
###xml 1124 1133 1124 1133 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">Cyclin D1</td>
###xml 1124 1133 1124 1133 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">Cyclin D1</td></tr>
###xml 1133 1139 1133 1139 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Low</td>
###xml 1139 1146 1139 1146 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">85 (73)</td>
###xml 1146 1154 1146 1154 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12 (1.9)</td>
###xml 1154 1159 1154 1159 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.002</td>
###xml 1133 1159 1133 1159 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">85 (73)</td><td char="." align="char">12 (1.9)</td><td char="." align="char">0.002</td></tr>
###xml 1159 1166 1159 1166 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;High</td>
###xml 1166 1173 1166 1173 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">32 (27)</td>
###xml 1173 1180 1173 1180 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7 (2.6)</td>
###xml 1180 1180 1180 1180 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1159 1180 1159 1180 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">32 (27)</td><td char="." align="char">7 (2.6)</td><td char="." align="char"/></tr>
###xml 1180 1183 1180 1183 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="4">p53</td>
###xml 1180 1183 1180 1183 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="4">p53</td></tr>
###xml 1183 1189 1183 1189 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;Low</td>
###xml 1189 1196 1189 1196 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">88 (75)</td>
###xml 1196 1203 1196 1203 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8 (1.3)</td>
###xml 1203 1209 1203 1209 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.001</td>
###xml 1183 1209 1183 1209 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">88 (75)</td><td char="." align="char">8 (1.3)</td><td char="." align="char">&lt;0.001</td></tr>
###xml 1209 1216 1209 1216 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;High</td>
###xml 1216 1223 1216 1223 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">29 (25)</td>
###xml 1223 1231 1223 1231 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">19 (4.3)</td>
###xml 1231 1231 1231 1231 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1209 1231 1209 1231 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">29 (25)</td><td char="." align="char">19 (4.3)</td><td char="." align="char"/></tr>
###xml 876 1231 876 1231 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Total</td><td char="(" align="char">117 (100)</td><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="4">ER</td></tr><tr><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">56 (48)</td><td char="." align="char">14 (2.5)</td><td char="." align="char">0.019</td></tr><tr><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">61 (52)</td><td char="." align="char">8 (1.6)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">PR</td></tr><tr><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">81 (69)</td><td char="." align="char">17 (1.9)</td><td char="." align="char">0.016</td></tr><tr><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">36 (31)</td><td char="." align="char">12 (1.9)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">HER-2/<italic>neu</italic></td></tr><tr><td align="left">&#160;&#160;&#160;Negative</td><td char="(" align="char">93 (79)</td><td char="." align="char">16 (1.6)</td><td char="." align="char">0.797</td></tr><tr><td align="left">&#160;&#160;&#160;Positive</td><td char="(" align="char">24 (21)</td><td char="." align="char">17 (3.5)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">EGF receptor</td></tr><tr><td align="left">&#160;&#160;&#160;Negative</td><td char="(" align="char">78 (66)</td><td char="." align="char">13 (1.5)</td><td char="." align="char">0.002</td></tr><tr><td align="left">&#160;&#160;&#160;Positive</td><td char="(" align="char">39 (33)</td><td char="." align="char">19 (3.1)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">Cyclin D1</td></tr><tr><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">85 (73)</td><td char="." align="char">12 (1.9)</td><td char="." align="char">0.002</td></tr><tr><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">32 (27)</td><td char="." align="char">7 (2.6)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">p53</td></tr><tr><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">88 (75)</td><td char="." align="char">8 (1.3)</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">29 (25)</td><td char="." align="char">19 (4.3)</td><td char="." align="char"/></tr></tbody>
###xml 830 1231 830 1231 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Number (%)</th><th align="left">Mean (SE) of FANCD2%</th><th align="left"><italic>p</italic> Value (<italic>t</italic> test)</th></tr></thead><tbody><tr><td align="left">Total</td><td char="(" align="char">117 (100)</td><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="4">ER</td></tr><tr><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">56 (48)</td><td char="." align="char">14 (2.5)</td><td char="." align="char">0.019</td></tr><tr><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">61 (52)</td><td char="." align="char">8 (1.6)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">PR</td></tr><tr><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">81 (69)</td><td char="." align="char">17 (1.9)</td><td char="." align="char">0.016</td></tr><tr><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">36 (31)</td><td char="." align="char">12 (1.9)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">HER-2/<italic>neu</italic></td></tr><tr><td align="left">&#160;&#160;&#160;Negative</td><td char="(" align="char">93 (79)</td><td char="." align="char">16 (1.6)</td><td char="." align="char">0.797</td></tr><tr><td align="left">&#160;&#160;&#160;Positive</td><td char="(" align="char">24 (21)</td><td char="." align="char">17 (3.5)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">EGF receptor</td></tr><tr><td align="left">&#160;&#160;&#160;Negative</td><td char="(" align="char">78 (66)</td><td char="." align="char">13 (1.5)</td><td char="." align="char">0.002</td></tr><tr><td align="left">&#160;&#160;&#160;Positive</td><td char="(" align="char">39 (33)</td><td char="." align="char">19 (3.1)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">Cyclin D1</td></tr><tr><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">85 (73)</td><td char="." align="char">12 (1.9)</td><td char="." align="char">0.002</td></tr><tr><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">32 (27)</td><td char="." align="char">7 (2.6)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">p53</td></tr><tr><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">88 (75)</td><td char="." align="char">8 (1.3)</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">29 (25)</td><td char="." align="char">19 (4.3)</td><td char="." align="char"/></tr></tbody></table>
###xml 1231 1233 1231 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 1253 1255 1253 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PR</italic>
###xml 1231 1277 1231 1277 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="22"><italic>ER</italic> estrogen receptor, <italic>PR</italic> progesterone receptor</p>
###xml 1231 1277 1231 1277 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="22"><italic>ER</italic> estrogen receptor, <italic>PR</italic> progesterone receptor</p></table-wrap-foot>
###xml 634 1277 634 1277 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="21">Mean percentage of FANCD2-positive cells in high- and low-level expression groups of hormone receptors, growth factor receptors, Cyclin D1, and p53 in sporadic and hereditary breast cancers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Number (%)</th><th align="left">Mean (SE) of FANCD2%</th><th align="left"><italic>p</italic> Value (<italic>t</italic> test)</th></tr></thead><tbody><tr><td align="left">Total</td><td char="(" align="char">117 (100)</td><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="4">ER</td></tr><tr><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">56 (48)</td><td char="." align="char">14 (2.5)</td><td char="." align="char">0.019</td></tr><tr><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">61 (52)</td><td char="." align="char">8 (1.6)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">PR</td></tr><tr><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">81 (69)</td><td char="." align="char">17 (1.9)</td><td char="." align="char">0.016</td></tr><tr><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">36 (31)</td><td char="." align="char">12 (1.9)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">HER-2/<italic>neu</italic></td></tr><tr><td align="left">&#160;&#160;&#160;Negative</td><td char="(" align="char">93 (79)</td><td char="." align="char">16 (1.6)</td><td char="." align="char">0.797</td></tr><tr><td align="left">&#160;&#160;&#160;Positive</td><td char="(" align="char">24 (21)</td><td char="." align="char">17 (3.5)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">EGF receptor</td></tr><tr><td align="left">&#160;&#160;&#160;Negative</td><td char="(" align="char">78 (66)</td><td char="." align="char">13 (1.5)</td><td char="." align="char">0.002</td></tr><tr><td align="left">&#160;&#160;&#160;Positive</td><td char="(" align="char">39 (33)</td><td char="." align="char">19 (3.1)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">Cyclin D1</td></tr><tr><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">85 (73)</td><td char="." align="char">12 (1.9)</td><td char="." align="char">0.002</td></tr><tr><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">32 (27)</td><td char="." align="char">7 (2.6)</td><td char="." align="char"/></tr><tr><td align="left" colspan="4">p53</td></tr><tr><td align="left">&#160;&#160;&#160;Low</td><td char="(" align="char">88 (75)</td><td char="." align="char">8 (1.3)</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">&#160;&#160;&#160;High</td><td char="(" align="char">29 (25)</td><td char="." align="char">19 (4.3)</td><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p textid="22"><italic>ER</italic> estrogen receptor, <italic>PR</italic> progesterone receptor</p></table-wrap-foot></table-wrap>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 121 129 <span type="species:ncbi:9606">patients</span>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
The mean percentage of FANCD2-expressing cells was significantly higher in ER-negative patients (p = 0.019), PR-negative patients (p = 0.016), EGFR-positive patients (p = 0.002), Cyclin-D1-negative patients (p = 0.002), and p53-positive patients (p < 0.001) (Table 2). No statistically significant difference was seen for HER-2/neu. When analyzing the sporadic and hereditary subgroups, similar associations were seen. FANCD2 staining intensity yielded no useful correlations and no prognostic value, and the FANCD2 score yielded essentially the same correlations and prognostic value as the % FANCD2-positive cells (data not shown). Table 2Mean percentage of FANCD2-positive cells in high- and low-level expression groups of hormone receptors, growth factor receptors, Cyclin D1, and p53 in sporadic and hereditary breast cancersNumber (%)Mean (SE) of FANCD2%p Value (t test)Total117 (100)ER   Low56 (48)14 (2.5)0.019   High61 (52)8 (1.6)PR   Low81 (69)17 (1.9)0.016   High36 (31)12 (1.9)HER-2/neu   Negative93 (79)16 (1.6)0.797   Positive24 (21)17 (3.5)EGF receptor   Negative78 (66)13 (1.5)0.002   Positive39 (33)19 (3.1)Cyclin D1   Low85 (73)12 (1.9)0.002   High32 (27)7 (2.6)p53   Low88 (75)8 (1.3)<0.001   High29 (25)19 (4.3)ER estrogen receptor, PR progesterone receptor
###end p 20
###begin p 21
Mean percentage of FANCD2-positive cells in high- and low-level expression groups of hormone receptors, growth factor receptors, Cyclin D1, and p53 in sporadic and hereditary breast cancers
###end p 21
###begin p 22
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 22 24 22 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PR</italic>
ER estrogen receptor, PR progesterone receptor
###end p 22
###begin p 23
###xml 37 38 37 38 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 167 168 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 178 179 178 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 196 197 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 207 208 207 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 228 229 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 239 240 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 300 301 300 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 311 312 311 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 327 328 327 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 338 339 338 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 358 359 358 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 369 370 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 463 464 463 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 691 692 691 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 709 710 709 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 725 726 725 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 740 741 740 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 818 825 818 825 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 825 980 825 980 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24">Correlation between mean percentage of FANCD2-expressing cells and other continuous clinicopathological variables in sporadic and hereditary breast cancers</p>
###xml 825 980 825 980 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24">Correlation between mean percentage of FANCD2-expressing cells and other continuous clinicopathological variables in sporadic and hereditary breast cancers</p></caption>
###xml 980 987 980 987 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Feature</th>
###xml 987 988 987 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 987 988 987 988 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>R</italic></th>
###xml 988 989 988 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 988 995 988 995 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>p</italic> Value</th>
###xml 980 995 980 995 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Feature</th><th align="left"><italic>R</italic></th><th align="left"><italic>p</italic> Value</th></tr>
###xml 980 995 980 995 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Feature</th><th align="left"><italic>R</italic></th><th align="left"><italic>p</italic> Value</th></tr></thead>
###xml 998 999 998 999 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 995 999 995 999 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MAI<sup>a</sup></td>
###xml 999 1004 999 1004 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.506</td>
###xml 1004 1010 1004 1010 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.001</td>
###xml 995 1010 995 1010 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">MAI<sup>a</sup></td><td char="." align="char">0.506</td><td char="." align="char">&lt;0.001</td></tr>
###xml 1015 1016 1015 1016 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1010 1016 1010 1016 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ki-67<sup>a</sup></td>
###xml 1016 1021 1016 1021 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.502</td>
###xml 1021 1027 1021 1027 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.001</td>
###xml 1010 1027 1010 1027 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Ki-67<sup>a</sup></td><td char="." align="char">0.502</td><td char="." align="char">&lt;0.001</td></tr>
###xml 1035 1036 1035 1036 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1027 1036 1027 1036 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cyclin A<sup>a</sup></td>
###xml 1036 1041 1036 1041 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.482</td>
###xml 1041 1047 1041 1047 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.001</td>
###xml 1027 1047 1027 1047 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Cyclin A<sup>a</sup></td><td char="." align="char">0.482</td><td char="." align="char">&lt;0.001</td></tr>
###xml 1047 1050 1047 1050 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age</td>
###xml 1050 1056 1050 1056 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.197</td>
###xml 1056 1061 1056 1061 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.033</td>
###xml 1047 1061 1047 1061 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Age</td><td char="." align="char">&#8722;0.197</td><td char="." align="char">0.033</td></tr>
###xml 1061 1063 1061 1063 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ER</td>
###xml 1063 1069 1063 1069 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.221</td>
###xml 1069 1074 1069 1074 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.017</td>
###xml 1061 1074 1061 1074 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">ER</td><td char="." align="char">&#8722;0.221</td><td char="." align="char">0.017</td></tr>
###xml 1074 1076 1074 1076 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PR</td>
###xml 1076 1082 1076 1082 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.204</td>
###xml 1082 1087 1082 1087 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.028</td>
###xml 1074 1087 1074 1087 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">PR</td><td char="." align="char">&#8722;0.204</td><td char="." align="char">0.028</td></tr>
###xml 1087 1097 1087 1097 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tumor size</td>
###xml 1097 1102 1097 1102 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.018</td>
###xml 1102 1107 1102 1107 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.852</td>
###xml 1087 1107 1087 1107 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Tumor size</td><td char="." align="char">0.018</td><td char="." align="char">0.852</td></tr>
###xml 1107 1110 1107 1110 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">p27</td>
###xml 1110 1116 1110 1116 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.074</td>
###xml 1116 1121 1116 1121 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.430</td>
###xml 1107 1121 1107 1121 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">p27</td><td char="." align="char">&#8722;0.074</td><td char="." align="char">0.430</td></tr>
###xml 1121 1124 1121 1124 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">p21</td>
###xml 1124 1130 1124 1130 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.171</td>
###xml 1130 1135 1130 1135 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.065</td>
###xml 1121 1135 1121 1135 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">p21</td><td char="." align="char">&#8722;0.171</td><td char="." align="char">0.065</td></tr>
###xml 1135 1138 1135 1138 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">p53</td>
###xml 1138 1143 1138 1143 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.379</td>
###xml 1143 1149 1143 1149 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.001</td>
###xml 1135 1149 1135 1149 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">p53</td><td char="." align="char">0.379</td><td char="." align="char">&lt;0.001</td></tr>
###xml 1149 1158 1149 1158 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Cyclin D1</td>
###xml 1158 1164 1158 1164 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.126</td>
###xml 1164 1169 1164 1169 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.176</td>
###xml 1149 1169 1149 1169 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Cyclin D1</td><td char="." align="char">&#8722;0.126</td><td char="." align="char">0.176</td></tr>
###xml 995 1169 995 1169 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">MAI<sup>a</sup></td><td char="." align="char">0.506</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">Ki-67<sup>a</sup></td><td char="." align="char">0.502</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">Cyclin A<sup>a</sup></td><td char="." align="char">0.482</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">Age</td><td char="." align="char">&#8722;0.197</td><td char="." align="char">0.033</td></tr><tr><td align="left">ER</td><td char="." align="char">&#8722;0.221</td><td char="." align="char">0.017</td></tr><tr><td align="left">PR</td><td char="." align="char">&#8722;0.204</td><td char="." align="char">0.028</td></tr><tr><td align="left">Tumor size</td><td char="." align="char">0.018</td><td char="." align="char">0.852</td></tr><tr><td align="left">p27</td><td char="." align="char">&#8722;0.074</td><td char="." align="char">0.430</td></tr><tr><td align="left">p21</td><td char="." align="char">&#8722;0.171</td><td char="." align="char">0.065</td></tr><tr><td align="left">p53</td><td char="." align="char">0.379</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">Cyclin D1</td><td char="." align="char">&#8722;0.126</td><td char="." align="char">0.176</td></tr></tbody>
###xml 980 1169 980 1169 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Feature</th><th align="left"><italic>R</italic></th><th align="left"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="left">MAI<sup>a</sup></td><td char="." align="char">0.506</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">Ki-67<sup>a</sup></td><td char="." align="char">0.502</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">Cyclin A<sup>a</sup></td><td char="." align="char">0.482</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">Age</td><td char="." align="char">&#8722;0.197</td><td char="." align="char">0.033</td></tr><tr><td align="left">ER</td><td char="." align="char">&#8722;0.221</td><td char="." align="char">0.017</td></tr><tr><td align="left">PR</td><td char="." align="char">&#8722;0.204</td><td char="." align="char">0.028</td></tr><tr><td align="left">Tumor size</td><td char="." align="char">0.018</td><td char="." align="char">0.852</td></tr><tr><td align="left">p27</td><td char="." align="char">&#8722;0.074</td><td char="." align="char">0.430</td></tr><tr><td align="left">p21</td><td char="." align="char">&#8722;0.171</td><td char="." align="char">0.065</td></tr><tr><td align="left">p53</td><td char="." align="char">0.379</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">Cyclin D1</td><td char="." align="char">&#8722;0.126</td><td char="." align="char">0.176</td></tr></tbody></table>
###xml 1169 1171 1169 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 1191 1193 1191 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PR</italic>
###xml 1169 1215 1169 1215 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25"><italic>ER</italic> estrogen receptor, <italic>PR</italic> progesterone receptor</p>
###xml 1215 1216 1215 1216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1215 1246 1215 1246 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26"><sup>a</sup>FANCD2-negative cases excluded</p>
###xml 1169 1246 1169 1246 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="25"><italic>ER</italic> estrogen receptor, <italic>PR</italic> progesterone receptor</p><p textid="26"><sup>a</sup>FANCD2-negative cases excluded</p></table-wrap-foot>
###xml 818 1246 818 1246 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="24">Correlation between mean percentage of FANCD2-expressing cells and other continuous clinicopathological variables in sporadic and hereditary breast cancers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Feature</th><th align="left"><italic>R</italic></th><th align="left"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="left">MAI<sup>a</sup></td><td char="." align="char">0.506</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">Ki-67<sup>a</sup></td><td char="." align="char">0.502</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">Cyclin A<sup>a</sup></td><td char="." align="char">0.482</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">Age</td><td char="." align="char">&#8722;0.197</td><td char="." align="char">0.033</td></tr><tr><td align="left">ER</td><td char="." align="char">&#8722;0.221</td><td char="." align="char">0.017</td></tr><tr><td align="left">PR</td><td char="." align="char">&#8722;0.204</td><td char="." align="char">0.028</td></tr><tr><td align="left">Tumor size</td><td char="." align="char">0.018</td><td char="." align="char">0.852</td></tr><tr><td align="left">p27</td><td char="." align="char">&#8722;0.074</td><td char="." align="char">0.430</td></tr><tr><td align="left">p21</td><td char="." align="char">&#8722;0.171</td><td char="." align="char">0.065</td></tr><tr><td align="left">p53</td><td char="." align="char">0.379</td><td char="." align="char">&lt;0.001</td></tr><tr><td align="left">Cyclin D1</td><td char="." align="char">&#8722;0.126</td><td char="." align="char">0.176</td></tr></tbody></table><table-wrap-foot><p textid="25"><italic>ER</italic> estrogen receptor, <italic>PR</italic> progesterone receptor</p><p textid="26"><sup>a</sup>FANCD2-negative cases excluded</p></table-wrap-foot></table-wrap>
###xml 1246 1252 1246 1252 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1352 1360 1352 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Top left</italic>
###xml 1378 1387 1378 1387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Top right</italic>
###xml 1406 1417 1406 1417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bottom left</italic>
###xml 1252 1495 1252 1495 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">FANCD2/Ki-67 immunofluorescence double staining in a representative case of invasive breast cancer. <italic>Top left</italic>: Ki-67 staining. <italic>Top right</italic>: FANCD2 staining. <italic>Bottom left</italic>: TO-PRO staining. D: Triple exposure showing coexpression of FANCD2 and Ki-67</p>
###xml 1252 1495 1252 1495 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">FANCD2/Ki-67 immunofluorescence double staining in a representative case of invasive breast cancer. <italic>Top left</italic>: Ki-67 staining. <italic>Top right</italic>: FANCD2 staining. <italic>Bottom left</italic>: TO-PRO staining. D: Triple exposure showing coexpression of FANCD2 and Ki-67</p></caption>
###xml 1495 1495 1495 1495 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10549_2007_9534_Fig2_HTML" id="MO2"/>
###xml 1246 1495 1246 1495 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="27">FANCD2/Ki-67 immunofluorescence double staining in a representative case of invasive breast cancer. <italic>Top left</italic>: Ki-67 staining. <italic>Top right</italic>: FANCD2 staining. <italic>Bottom left</italic>: TO-PRO staining. D: Triple exposure showing coexpression of FANCD2 and Ki-67</p></caption><graphic position="anchor" xlink:href="10549_2007_9534_Fig2_HTML" id="MO2"/></fig>
###xml 191 194 <span type="species:ncbi:55883?0.49606299212598426">MAI</span>
In linear regression analysis (Table 3), the percentage of FANCD2-expressing cells was significantly positively correlated to Ki-67 (R = 0.502, p < 0.0001), Cyclin A (R = 0.482, p < 0.0001), MAI (R = 0.506, p < 0.001), and p53 (R = 0.379, p < 0.0001), and significantly negatively correlated to age (R = 0.197, p = 0.033), ER (R = 0.221, p = 0.017), and PR (R = 0.204, p = 0.028). There was no correlation between FANCD2 and the other continuous features. Figure 2 shows examples of FANCD2/Ki-67 immunofluorescence double staining, underlining the coexpression of FANCD2 and Ki-67 in invasive breast cancers cells. In the Muenster cases, most of these correlations could be reproduced (age: p = 0.063, Ki-67: p = 0.001, p53: p = 0.003, ER: p = 0.034). Only PR was not significant here, and Cyclin A was not performed. Table 3Correlation between mean percentage of FANCD2-expressing cells and other continuous clinicopathological variables in sporadic and hereditary breast cancersFeatureRp ValueMAIa0.506<0.001Ki-67a0.502<0.001Cyclin Aa0.482<0.001Age-0.1970.033ER-0.2210.017PR-0.2040.028Tumor size0.0180.852p27-0.0740.430p21-0.1710.065p530.379<0.001Cyclin D1-0.1260.176ER estrogen receptor, PR progesterone receptoraFANCD2-negative cases excludedFig. 2FANCD2/Ki-67 immunofluorescence double staining in a representative case of invasive breast cancer. Top left: Ki-67 staining. Top right: FANCD2 staining. Bottom left: TO-PRO staining. D: Triple exposure showing coexpression of FANCD2 and Ki-67
###end p 23
###begin p 24
Correlation between mean percentage of FANCD2-expressing cells and other continuous clinicopathological variables in sporadic and hereditary breast cancers
###end p 24
###begin p 25
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER</italic>
###xml 22 24 22 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PR</italic>
ER estrogen receptor, PR progesterone receptor
###end p 25
###begin p 26
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aFANCD2-negative cases excluded
###end p 26
###begin p 27
###xml 100 108 100 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Top left</italic>
###xml 126 135 126 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Top right</italic>
###xml 154 165 154 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bottom left</italic>
FANCD2/Ki-67 immunofluorescence double staining in a representative case of invasive breast cancer. Top left: Ki-67 staining. Top right: FANCD2 staining. Bottom left: TO-PRO staining. D: Triple exposure showing coexpression of FANCD2 and Ki-67
###end p 27
###begin p 28
###xml 277 280 <span type="species:ncbi:55883?0.49606299212598426">MAI</span>
In the regression analysis between the percentages of FANCD2-expressing cells and Ki-67 and Cyclin A, the completely negative FANCD2 cases were excluded. These FANCD2-negative cases had Ki-67 values between 1 and 65 (mean 16%), Cyclin A values between 0 and 50 (mean 10%), and MAI values between 0 and 37 (mean 11), indicating that these cases had (sometimes even high) FANCD2-independent proliferation.
###end p 28
###begin p 29
###xml 114 115 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 319 320 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 331 337 331 337 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 471 472 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 481 482 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 337 489 337 489 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Prognostic value of FANCD2 expression in sporadic invasive breast cancer. Low expressors have a better survival than high expressors (<italic>p</italic>&#160;=&#160;0.03, <italic>N</italic>&#160;=&#160;122)</p>
###xml 337 489 337 489 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Prognostic value of FANCD2 expression in sporadic invasive breast cancer. Low expressors have a better survival than high expressors (<italic>p</italic>&#160;=&#160;0.03, <italic>N</italic>&#160;=&#160;122)</p></caption>
###xml 489 489 489 489 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10549_2007_9534_Fig3_HTML" id="MO3"/>
###xml 331 489 331 489 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="30">Prognostic value of FANCD2 expression in sporadic invasive breast cancer. Low expressors have a better survival than high expressors (<italic>p</italic>&#160;=&#160;0.03, <italic>N</italic>&#160;=&#160;122)</p></caption><graphic position="anchor" xlink:href="10549_2007_9534_Fig3_HTML" id="MO3"/></fig>
In survival analysis (sporadic Muenster cases), high FANCD2 expression appeared to be prognostically unfavorable (p = 0.03). Figure 3 shows the survival curves. In Cox regression including tumor size, lymph node status, ER, and grade, FANCD2 staining appeared to have independent prognostic value for overall survival (p = 0.026). Fig. 3Prognostic value of FANCD2 expression in sporadic invasive breast cancer. Low expressors have a better survival than high expressors (p = 0.03, N = 122)
###end p 29
###begin p 30
###xml 134 135 134 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
Prognostic value of FANCD2 expression in sporadic invasive breast cancer. Low expressors have a better survival than high expressors (p = 0.03, N = 122)
###end p 30
###begin title 31
Discussion
###end title 31
###begin p 32
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
The aim of this study was to investigate the expression of FANCD2 in sporadic and hereditary breast cancers. This was inspired by several observations. First, FANCD2 and BRCA1/2 are functionally closely linked in the DNA repair response, and BRCA1 and BRCA2 are implicated in hereditary and sporadic breast cancers [21, 22]. Second, targeted deletion of FANCD2 in mice resulted in an increased rate of breast tumors [24]. Third, we have shown that FANCD2 is expressed in proliferating cells in the duct epithelium of the normal breast [23].
###end p 32
###begin p 33
###xml 153 156 <span type="species:ncbi:55883?0.49606299212598426">MAI</span>
It appeared that 19% of sporadic breast cancers completely lacked FANCD2 expression. Yet, these FANCD2-negative cases had high mean Ki-67, Cyclin A, and MAI values, indicating that the low FANCD2 levels in these cases cannot be explained by low proliferation. The fact that these FANCD2-negative cases stained for other proteins makes it quite unlikely that the FANCD2 negativity is due to fixation problems. In the FANCD2-negative cases, FANCD2 inactivation may, in view of its important function, have been a hit in carcinogenesis. BRCA1 germline mutation-related breast cancers showed lack of FANCD2 expression in only 9.5% of cases, which fits with the concept that a major hit in an important pathway (in these cases the BRCA1 germline mutation) is usually not associated with further hits in this pathway. It is yet unclear what the mechanism behind the lack of FANCD2 expression in these cases is. It needs to be further studied whether there are inactivating somatic mutations in these cases or whether promoter methylation plays a role.
###end p 33
###begin p 34
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 120 123 <span type="species:ncbi:55883?0.49606299212598426">MAI</span>
###xml 480 485 <span type="species:ncbi:9606">human</span>
FANCD2 expression was strongly correlated with expression of the proliferation-associated features Ki-67, Cyclin A, and MAI, and FANCD2 and Ki-67 were coexpressed in invasive cancer cells. This is likely a reflection of the physiological function of FANCD2 in DNA repair of proliferating cells, rather than an independent overexpression of an altered gene, in line with our previous study where we found a coexpression of FANCD2 and Ki-67 in proliferating cells of various normal human tissues [23]. The observation that high FANCD2 expression indicated poor prognosis fits within the same concept, as rate of proliferation (and thereby FANCD2 expression) is a major cell biological phenomenon determining prognosis [31-33]. FANCD2 had prognostic value independent of stage and grade, which can be explained by the fact that proliferation and stage are not strongly correlated, and that grade includes nuclear atypia and tubule formation besides rate of proliferation as measured by mitotic index.
###end p 34
###begin p 35
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
Although heterozygosity for p53 was shown to accelerate epithelial tumor formation in Fancd2 knockout mice [34], a functional link between p53 and Fancd2 has not been described to explain the association found in the present study, which is likely caused by the fact that p53 mutated and thereby p53 protein accumulated tumors show, in general, higher proliferation and therefore more proliferating FANCD2-expressing cells. The same may also hold for the relation between FANCD2 and EGFR expressions, for which also no functional relationship has been described.
###end p 35
###begin p 36
###xml 100 108 <span type="species:ncbi:9606">patients</span>
The negative relation between FANCD2 and age can likely be explained by the fact that BRCA1-related patients that have higher FANCD2 expression are younger.
###end p 36
###begin p 37
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 273 281 <span type="species:ncbi:9606">patients</span>
###xml 564 572 <span type="species:ncbi:9606">patients</span>
Within the light of the above observations, the question remains why FANCD2 patients do not seem to be predisposed to breast cancer in clinical practice. FA itself is a rare genetic disease where the complementation group D2 constitutes only 1-2% of all FA cases and these patients generally have a more severe clinical course. They may therefore simply not live to get breast cancer in an apparent increased frequency. Our results do not indicate that somatic (epi)genetic changes in FANCD2 are a frequent secondary carcinogenetic event in BRCA1 germline-mutated patients, although this needs to be confirmed in a larger study group.
###end p 37
###begin p 38
In conclusion, FANCD2 expression is absent in 10-20% of sporadic and BRCA1-related breast cancers, indicating that somatic inactivating (epi)genetic events in FANCD2 may be important in both sporadic and hereditary breast carcinogenesis. FANCD2 is of independent prognostic value in sporadic breast cancer.
###end p 38
###begin p 39
We thank Dick van Wichen, Jurryt van der Gugten, and Lennert Ploeger for their expert help with the immunofluorescence double staining. This work was supported by grants from the Maurits Anna de Kock foundation, the Dutch Organization for Scientific Research and the Dutch Cancer Society (VU2001-2505), and the First Aegon International Scholarship in Oncology.
###end p 39
###begin title 40
References
###end title 40
###begin article-title 41
The emerging genetic and molecular basis of Fanconi anaemia
###end article-title 41
###begin article-title 42
The Fanconi anaemia/BRCA pathway
###end article-title 42
###begin article-title 43
Positional cloning of a novel Fanconi anemia gene, FANCD2
###end article-title 43
###begin article-title 44
Cloning of cDNAs for Fanconi's anaemia by functional complementation
###end article-title 44
###begin article-title 45
The Fanconi anaemia group G gene FANCG is identical with XRCC9
###end article-title 45
###begin article-title 46
Isolation of a cDNA representing the Fanconi anemia complementation group E gene
###end article-title 46
###begin article-title 47
The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM
###end article-title 47
###begin article-title 48
Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA
###end article-title 48
###begin article-title 49
Biallelic inactivation of BRCA2 in Fanconi anemia
###end article-title 49
###begin article-title 50
Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway
###end article-title 50
###begin article-title 51
A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA
###end article-title 51
###begin article-title 52
###xml 58 64 <span type="species:ncbi:10090">murine</span>
Characterization, expression and complex formation of the murine Fanconi anaemia gene product FANCG
###end article-title 52
###begin article-title 53
Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes
###end article-title 53
###begin article-title 54
###xml 2 7 <span type="species:ncbi:9606">human</span>
A human ortholog of archael DNA repair protein Hef is defective in Fanconi anemia complementation group M
###end article-title 54
###begin article-title 55
X-linked inheritance of Fanconi anemia complementation group B
###end article-title 55
###begin article-title 56
A novel ubiquitin ligase is deficient in Fanconi anemia
###end article-title 56
###begin article-title 57
The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANC and FANCG
###end article-title 57
###begin article-title 58
New advances in the DNA damage response network of Fanconi anemia and BRCA proteins: FAAP95 replaces BRCA2 as the true FANCB protein
###end article-title 58
###begin article-title 59
Tracing the network connecting BRCA and Fanconi anemia proteins
###end article-title 59
###begin article-title 60
BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo
###end article-title 60
###begin article-title 61
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
###end article-title 61
###begin article-title 62
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression
###end article-title 62
###begin article-title 63
###xml 54 59 <span type="species:ncbi:9606">human</span>
FANCD2 protein is expressed in proliferating cells of human tissues that are cancer-prone in Fanconi anemia
###end article-title 63
###begin article-title 64
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice
###end article-title 64
###begin article-title 65
Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer
###end article-title 65
###begin article-title 66
Demystified tissue microarray technology
###end article-title 66
###begin article-title 67
First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer
###end article-title 67
###begin article-title 68
No consent should be needed for using leftover body material for scientific purposes
###end article-title 68
###begin article-title 69
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment
###end article-title 69
###begin article-title 70
Development of 3D chromatin texture analysis using confocal laser scanning microscopy
###end article-title 70
###begin article-title 71
Prognostic value of proliferation in invasive breast cancer: a review
###end article-title 71
###begin article-title 72
###xml 160 168 <span type="species:ncbi:9606">patients</span>
The morphometric Multivariate Prognostic Index (MPI) is the strongest prognosticator in premenopausal lymph node negative and lymph node positive breast cancer patients
###end article-title 72
###begin article-title 73
###xml 138 146 <span type="species:ncbi:9606">patients</span>
Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years
###end article-title 73
###begin article-title 74
###xml 134 138 <span type="species:ncbi:10090">mice</span>
Heterozygosity for p53 (Trp53+/?) accelerates epithelial tumor formation in Fanconi anemia complementation group D2 (Fancd2) knockout mice
###end article-title 74
###begin p 75
Petra van der Groep and Michael Hoelzel contributed equally to this study.
###end p 75

